Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies

Current Pharmaceutical Design

Volumn 13, Issue 20, 2007, Pages 2025-2044

  Rusnati, M ^a   Presta, M ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Angiogenesis; Endothelium; FGF; FGF receptors; Inhibitors

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AE 941; ARISTOLOCHIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CERIVASTATIN; CIDOFOVIR; CISPLATIN; CURCUMIN; DOCETAXEL; DOXYCYCLINE; EPIGALLOCATECHIN GALLATE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR; GANGLIOSIDE; GEFITINIB; GENISTEIN; HERBIMYCIN; INDOMETACIN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NUTRACEUTICAL; RAPAMYCIN; SEMAXANIB; SPIRONOLACTONE; TAXANE DERIVATIVE; THALIDOMIDE; UNINDEXED DRUG; ZOLEDRONIC ACID;

AMINO ACID SEQUENCE; ANGIOGENESIS; BONE DISEASE; CELL TYPE; DRUG MECHANISM; EMBRYO DEVELOPMENT; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PURIFICATION; RETINITIS; REVIEW; RHINITIS; SIGNAL TRANSDUCTION; TUMOR GROWTH; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANIMALS; DRUG DESIGN; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 34447253095     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207781039689     Document Type: Review

References (292)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
3. Maciag T, Mehlman T, Friesel R, Schreiber AB. Heparin binds endothelial cell growth factor, the principal endothelial cell mitogen in bovine brain. Science 1984; 225: 932-5.
4. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004; 20: 563-9.
5. Presta M, Dell'era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 159-78.
6. Javerzat S, Auguste P, Bikfalvi A. The role of fibroblast growth factors in vascular development. Trends Mol Med 2002; 8: 483-9.
7. Liotta LA, Steeg PS, Stetler-Stevenson WG, Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327-36.
8. Rusnati M, Dell'Era P, Urbinati C, Tanghetti E, Massardi ML, Nagamine Y, et al. A distinct basic fibroblast growth factor (FGF-2)/FGF receptor interaction distinguishes urokinase-type plasminogen activator induction from mitogenicity in endothelial cells. Mol Biol Cell 1996; 7: 369-81.
9. Taraboletti G, D'Ascenzo S, Borsotti P, Giavazzi R, Pavan A, Dolo V. Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol 2002; 160: 673-80.
10. Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998; 95: 365-77.
11. Terranova VP, DiFlorio R, Lyall RM, Hic S, Friesel R, Maciag T. Human endothelial cells are chemotactic to endothelial cell growth factor and heparin. J Cell Biol 1985; 101: 2330-4.
12. Montesano R, Orci L, Vassalli P. In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol 1983; 97: 1648-52.
13. Montesano R, Vassalli JD, Baird A, Guillemin R, Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA 1986; 83: 7297-301.
14. Pepper MS, Belin D, Montesano R, Orci L, Vassalli JD. Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol 1990; 111: 743-55.
15. Henke CA, Roongta U, Mickelson DJ, Knutson JR, McCarthy JB. CD44-related chondroitin sulfate proteoglycan, a cell surface receptor implicated with tumor cell invasion, mediates endothelial cell migration on fibrinogen and invasion into a fibrin matrix. J Clin Invest 1996; 97: 2541-52.
16. Takei A, Tashiro Y, Nakashima Y, Sueishi K. Effects of fibrin on the angiogenesis in vitro of bovine endothelial cells in collagen gel. In Vitro Cell Dev Biol Anim 1995; 31: 467-72.
17. Kumar R, Yoneda J, Bucana CD, Fidler IJ. Regulation of distinct steps of angiogenesis by different angiogenic molecules. Int J Oncol 1998; 12: 749-57.
18. Schnaper HW, Grant DS, Stetler-Stevenson WG, Fridman R, D'Orazi G, Murphy AN, et al. Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol 1993; 156: 235-46.
19. Schnaper HW, Barnathan ES, Mazar A, Maheshwari S, Ellis S, Cortez SL, et al. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways. J Cell Physiol 1995; 165: 107-18.
20. Davis GE, Camarillo CW. Regulation of endothelial cell morphogenesis by integrins, mechanical forces, and matrix guidance pathways. Exp Cell Res 1995; 216: 113-23.
21. Underwood PA, Bean PA, Gamble JR. Rate of endothelial expansion is controlled by cell:cell adhesion. Int J Biochem Cell Biol 2002; 34: 55-69.
22. Klein S, Giancotti FG, Presta M, Albelda SM, Buck CA, Rifkin DB. Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells. Mol Biol Cell 1993; 4: 973-82.
23. Gerritsen ME, Soriano R, Yang S, Zlot C, Ingle G, Toy K, et al. Branching out: a molecular fingerprint of endothelial differentiation into tube-like structures generated by Affymetrix oligonucleotide arrays. Microcirculation 2003; 10: 63-81.
24. Ribatti D, Vacca A, Roncali L, Dammacco F. The chick embryo chorioallantoic membrane as a model for in vivo research on anti-angiogenesis. Curr Pharm Biotechnol 2000; 1: 73-82.
25. Herbert JM, Laplace MC, Maffrand JP. Effect of heparin on the angiogenic potency of basic and acidic fibroblast growth factors in the rabbit cornea assay. Int J Tissue React 1988; 10: 133-9.
26. Seghezzi G, Patel S, Ren CJ, Gualandris A, Pintucci G, Robbins ES, et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 1998; 141: 1659-73.
27. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992; 67: 519-28.
28. Liekens S, Neyts J, De Clercq E, Verbeken E, Ribatti D, Presta M. Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir. Cancer Res 2001; 61: 5057-64.
29. Ribatti D, Nico B, Morbidelli L, Donnini S, Ziche M, Vacca A, et al. Cell-mediated delivery of fibroblast growth factor-2 and vascular endothelial growth factor onto the chick chorioallantoic membrane: endothelial fenestration and angiogenesis. J Vasc Res 2001; 38: 389-97.
30. Rusnati M, Tanghetti E, Dell'Era P, Gualandris A, Presta M. alphavbeta3 integrin mediates the cell-adhesive capacity and biological activity of basic fibroblast growth factor (FGF-2) in cultured endothelial cells. Mol Biol Cell 1997; 8: 2449-61.
31. Rusnati M, Urbinati C, Tanghetti E, Dell'Era P, Lortat-Jacob H, Presta M. Cell membrane GM1 ganglioside is a functional coreceptor for fibroblast growth factor 2. Proc Natl Acad Sci USA 2002; 99: 4367-72.
32. Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 1993; 60: 1-41.
33. Yoon SY, Tefferi A, Li CY. Cellular distribution of platelet-derived growth factor, transforming growth factor-beta, basic fibroblast growth factor, and their receptors in normal bone marrow. Acta Haematol 2000; 104: 151-7.
34. Dell'Era P, Belleri M, Stabile H, Massardi ML, Ribatti D, Presta M. Paracrine and autocrine effects of fibroblast growth factor-4 in endothelial cells. Oncogene 2001; 20: 2655-63.
35. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16: 139-49.
36. Lindahl U. Lidholt K, Spillmann D, Kjellen L. More to "heparin" than anticoagulation. Thromb Res 1994; 75: 1-32.
37. Pellegrini L. Role of heparan sulfate in fibroblast growth factor signalling: a structural view. Curr Opin Struct Biol 2001; 11: 629-34.
38. Eriksson AE, Cousens LS, Weaver LH, Matthews BW. Three-dimensional structure of human basic fibroblast growth factor. Proc Natl Acad Sci USA 1991; 88: 3441-5.
39. Horowitz A, Tkachenko E, Simons M. Fibroblast growth factor-specific modulation of cellular response by syndecan-4. J Cell Biol 2002; 157: 715-25.
40. Chua CC, Rahimi N, Forsten-Williams K, Nugent MA. Heparan sulfate proteoglycans function as receptors for fibroblast growth factor-2 activation of extracellular signal-regulated kinases 1 and 2. Circ Res 2004; 94: 316-23.
41. Rusnati M, Urbinati C, Presta M. Internalization of basic fibroblast growth factor (bFGF) in cultured endothelial cells: role of the low affinity heparin-like bFGF receptors. J Cell Physiol 1993; 154: 152-61.
42. Rusnati M, Presta M. Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Biological implications in neovascularization. Int J Clin Lab Res 1996; 26: 15-23.
43. Coltrini D, Rusnati M, Zoppetti G, Oreste P, Grazioli G, Naggi A, et al. Different effects of mucosal, bovine lung and chemically modified heparin on selected biological properties of basic fibroblast growth factor. Biochem J 1994; 303 (Pt 2): 583-90.
44. Presta M, Maier JA, Rusnati M, Ragnotti G. Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form. J Cell Physiol 1989; 140: 68-74.
45. Vlodavsky I, Komer G, Ishai-Michaeli R, Bashkin P, Bar-Shavit R, Fuks Z. Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev 1990; 9: 203-26.
46. Ribatti D, Leali D, Vacca A, Giuliani R, Gualandris A, Roncali L, et al. In vivo angiogenic activity of urokinase: role of endogenous fibroblast growth factor-2. J Cell Sci 1999; 112 (Pt 23): 4213-21.
47. Ruegg C, Mariotti A. Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cell Mol Life Sci 2003; 60: 1135-57.
48. Eliceiri BP. Integrin and growth factor receptor crosstalk. Circ Res 2001; 89: 1104-10.
49. Kumar CC. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 2003; 4: 123-31.
50. Tanghetti E, Ria R, Dell'Era P, Urbinati C, Rusnati M, Ennas MG, et al. Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts. Oncogene 2002; 21: 3889-97.
51. Sahni A, Francis CW. Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires {alpha}v{beta}3. Blood 2004; 104: 3635-41.
52. Schlaepfer DD, Hauck CR, Sieg DJ. Signaling through focal adhesion kinase. Prog Biophys Mol Biol 1999; 71: 435-78.
53. Palazzo AF, Eng CH, Schlaepfer DD, Marcantonio EE, Gundersen GG. Localized stabilization of microtubules by integrin- and FAK-facilitated Rho signaling. Science 2004; 303: 836-9.
54. Zhai J, Lin H, Nie Z, Wu J, Canete-Soler R, Schlaepfer WW, et al. Direct interaction of focal adhesion kinase with p190RhoGEF. J Biol Chem 2003; 278: 24865-73.
55. Sharma-Walia N, Naranatt PP, Krishnan HH, Zeng L, Chandran B. Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 envelope glycoprotein gB induces the integrin-dependent focal adhesion kinase-Src-phosphatidylinositol 3-kinase-rho GTPase signal pathways and cytoskeletal rearrangements. J Virol 2004; 78: 4207-23.
56. Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF, Giachelli CM. NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J Cell Biol 1998; 141: 1083-93.
57. Presta M, Oreste P, Zoppetti G, Belleri M, Tanghetti E, Leali D, et al. Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists. Arterioscler Thromb Vasc Biol 2005; 25: 71-6.
58. Birkle S, Zeng G, Gao L, Yu RK, Aubry J. Role of tumor-associated gangliosides in cancer progression. Biochimie 2003; 85: 455-63.
59. Rusnati M, Tanghetti E, Urbinati C, Tulipano G, Marchesini S, Ziche M, et al. Interaction of fibroblast growth factor-2 (FGF-2) with free gangliosides: biochemical characterization and biological consequences in endothelial cell cultures. Mol Biol Cell 1999; 10: 313-27.
60. Miljan EA, Bremer EG. Regulation of growth factor receptors by gangliosides. Sci STKE 2002; 2002: RE15.
61. Gualandris A, Rusnati M, Belleri M, Nelli EE, Bastaki M, Molinari-Tosatti MP, et al. Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases. Cell Growth Differ 1996; 7: 147-60.
62. Bikfalvi A, Klein S, Pintucci G, Quarto N, Mignatti P, Rifkin DB. Differential modulation of cell phenotype by different molecular weight forms of basic fibroblast growth factor: possible intracellular signaling by the high molecular weight forms. J Cell Biol 1995; 129:233-43.
63. Florkiewicz RZ, Baird A, Gonzalez AM. Multiple forms of bFGF: differential nuclear and cell surface localization. Growth Factors 1991; 4: 265-75.
64. Quarto N, Talarico D, Florkiewicz R, Rifkin DB. Selective expression of high molecular weight basic fibroblast growth factor confers a unique phenotype to NIH 3T3 cells. Cell Regul 1991; 2: 699-708.
65. Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med 1997; 3: 887-93.
66. Ribatti D, Alessandri G, Baronio M, Raffaghello L, Cosimo E, Marimpietri D, et al. Inhibition of neuroblastoma-induced angiogenesis by fenretinide. Int J Cancer 2001; 94: 314-21.
67. Tsou R, Isik FF. Integrin activation is required for VEGF and FGF receptor protein presence on human microvascular endothelial cells. Mol Cell Biochem 2001; 224: 81-9.
68. Fujiwara Y, Kaji T. Possible mechanism for lead inhibition of vascular endothelial cell proliferation: a lower response to basic fibroblast growth factor through inhibition of heparan sulfate synthesis. Toxicology 1999; 133: 147-57.
69. Zhang W, Chuang YJ, Swanson R, Li J, Seo K, Leung L, et al. Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells. Blood 2004; 103: 1185-91.
70. Aviezer D, Iozzo RV, Noonan DM, Yayon A. Suppression of autocrine and paracrine functions of basic fibroblast growth factor by stable expression of perlecan antisense cDNA. Mol Cell Biol 1997; 17: 1938-46.
71. Wang S, Ai X, Freeman SD, Pownall ME, Lu Q, Kessler DS, et al. QSulf1, a heparan sulfate 6-O-endosulfatase, inhibits fibroblast growth factor signaling in mesoderm induction and angiogenesis. Proc Natl Acad Sci USA 2004; 101: 4833-8.
72. Cieslak M, Niewiarowska J, Nawrot M, Koziolkiewicz M, Stec WJ, Cierniewski CS. DNAzymes to beta 1 and beta 3 mRNA down-regulate expression of the targeted integrins and inhibit endothelial cell capillary tube formation in fibrin and matrigel. J Biol Chem 2002; 277: 6779-87.
73. Jee SH, Chu CY, Chiu HC, Huang YL, Tsai WL, Liao YH, et al. Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt pathways. J Invest Dermatol 2004; 123: 1169-75.
74. Ribatti D, Urbinati C, Nico B, Rusnati M, Roncali L, Presta M. Endogenous basic fibroblast growth factor is implicated in the vascularization of the chick embryo chorioallantoic membrane. Dev Biol 1995; 170: 39-49.
75. Bornstein P, Armstrong LC, Hankenson KD, Kyriakides TR, Yang Z. Thrombospondin 2, a matricellular protein with diverse functions. Matrix Biol 2000; 19: 557-68.
76. Taraboletti G, Belotti D, Borsotti P, Vergani V, Rusnati M, Presta M, et al. The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. Cell Growth Differ 1997; 8: 471-9.
77. Margosio B, Marchetti D, Vergani V, Giavazzi R, Rusnati M, Presta M, et al. Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood 2003; 102: 4399-406.
78. Bossard C, Van den Berghe L, Laurell H, Castano C, Cerutti M, Prats AC, et al. Antiangiogenic properties of fibstatin, an extracellular FGF-2-binding polypeptide. Cancer Res 2004; 64: 7507-12.
79. Asplin IR, Wu SM, Mathew S, Bhattacharjee G, Pizzo SV. Differential regulation of the fibroblast growth factor (FGF) family by alpha(2)-macroglobulin: evidence for selective modulation of FGF-2-induced angiogenesis. Blood 2001; 97: 3450-7.
80. Dennis PA, Saksela O, Harpel P, Rifkin DB. Alpha 2-macroglobulin is a binding protein for basic fibroblast growth factor. J Biol Chem 1989; 264: 7210-6.
81. Bottazzi B, Vouret-Craviari V, Bastone A, De Gioia L, Matteucci C, Peri G, et al. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem 1997; 272: 32817-23.
82. Breviario F, d'Aniello EM, Golay J, Peri G, Bottazzi B, Bairoch A, et al. Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem 1992; 267: 22190-7.
83. Rusnati M, Camozzi M, Moroni E, Bottazzi B, Peri G, Indraccolo S, et al. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood 2004; 104: 92-9.
84. Salustri A, Garlanda C, Hirsch E, De Acetis M, Maccagno A, Bottazzi B, et al. PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in in vivo fertilization. Development 2004; 131: 1577-86.
85. Perollet C, Han ZC, Savona C, Caen JP, Bikfalvi A. Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood 1998; 91: 3289-99.
86. Lozano RM, Redondo-Horcajo M, Jimenez MA, Zilberberg L, Cuevas P, Bikfalvi A, et al. Solution structure and interaction with basic and acidic fibroblast growth factor of a 3-kDa human platelet factor-4 fragment with antiangiogenic activity. J Biol Chem 2001; 276: 35723-34.
87. Hagedorn M, Zilberberg L, Wilting J, Canron X, Carrabba G, Giussani C, et al. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors. Cancer Res 2002; 62: 6884-90.
88. Russo K, Ragone R, Facchiano AM, Capogrossi MC, Facchiano A. Platelet-derived growth factor-BB and basic fibroblast growth factor directly interact in vitro with high affinity. J Biol Chem 2002; 277: 1284-91.
89. De Marchis F, Ribatti D, Giampietri C, Lentini A, Faraone D, Scoccianti M, et al. Platelet-derived growth factor inhibits basic fibroblast growth factor angiogenic properties in vitro and in vivo through its alpha receptor. Blood 2002; 99: 2045-53.
90. Spinetti G, Camarda G, Bernardini G, Romano Di Peppe S, Capogrossi MC, Napolitano M. The chemokine CXCL13 (BCA-1) inhibits FGF-2 effects on endothelial cells. Biochem Biophys Res Commun 2001; 289: 19-24.
91. Shellenberger TD, Wang M, Gujrati M, Jayakumar A, Strieter RM, Burdick MD, et al. BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res 2004; 64: 8262-70.
92. Hanneken A, Baird A. Soluble forms of the high-affinity fibroblast growth factor receptor in human vitreous fluid. Invest Ophthalmol Vis Sci 1995; 36: 1192-6.
93. Hanneken A, Maher PA, Baird A. High affinity immunoreactive FGF receptors in the extracellular matrix of vascular endothelial cells-implications for the modulation of FGF-2. J Cell Biol 1995; 128: 1221-8.
94. Bergonzoni L, Caccia P, Cletini O, Sarmientos P, Isacchi A. Characterization of a biologically active extracellular domain of fibroblast growth factor receptor 1 expressed in Escherichia coli. Eur J Biochem 1992; 210: 823-29.
95. Ueno H, Gunn M, Dell K, Tseng A Jr, Williams L. A truncated form of fibroblast growth factor receptor 1 inhibits signal transduction by multiple types of fibroblast growth factor receptor. J Biol Chem 1992; 267: 1470-6.
96. Presta M, Leali D, Stabile H, Ronca R, Camozzi M, Coco L, et al. Heparin derivatives as angiogenesis inhibitors. Curr Pharm Des 2003; 9: 553-66.
97. Barzu T, Lormeau JC, Petitou M, Michelson S, Choay J. Heparin-derived oligosaccharides: affinity for acidic fibroblast growth factor and effect on its growth-promoting activity for human endothelial cells. J Cell Physiol 1989; 140: 538-48.
98. Ishihara M, Shaklee PN, Yang Z, Liang W, Wei Z, Stack RJ, et al. Structural features in heparin which modulate specific biological activities mediated by basic fibroblast growth factor. Glycobiology 1994; 4: 451-8.
99. Leali D, Belleri M, Urbinati C, Coltrini D, Oreste P, Zoppetti G, et al. Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives. J Biol Chem 2001; 276: 37900-8.
100. Urbinati C, Bugatti A, Oreste P, Zoppetti G, Waltenberger J, Mitola S, et al. Chemically sulfated Escherichia coli K5 polysaccharide derivatives as extracellular HIV-1 Tat protein antagonists. FEBS Lett 2004; 568: 171-7.
101. Rusnati M, Urbinati C, Caputo A, Possati L, Lortat-Jacob H, Giacca M, et al. Pentosan polysulfate as an inhibitor of extracellular HIV-1 Tat. J Biol Chem 2001; 276: 22420-5.
102. Herbert JM, Cottineau M, Driot F, Pereillo JM, Maffrand JP. Activity of pentosan polysulphate and derived compounds on vascular endothelial cell proliferation and migration induced by acidic and basic FGF in vitro. Biochem Pharmacol 1988; 37: 4281-8.
103. Schwartsmann G, Sprinz E, Kalakun L, Yamagushi N, Sander E, Grivicich I, et al. Phase II study of pentosan polysulfate (PPS) in patients with AIDS-related Kaposi's sarcoma. Tumori 1996; 82: 360-3.
104. Ensoli B, Gendelman R, Markham P, Fiorelli V, Colombini S, Raffeld M, et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 1994; 371: 674-80.
105. Schilling-Schon A, Pleyer U, Hartmann C, Rieck PW. The role of endogenous growth factors to support corneal endothelial migration after wounding in vitro. Exp Eye Res 2000; 71: 583-9.
106. Facchiano A, Russo K, Facchiano AM, De Marchis F, Facchiano F, Ribatti D, et al. Identification of a novel domain of fibroblast growth factor 2 controlling its angiogenic properties. J Biol Chem 2003; 278: 8751-60.
107. Ding L, Donate F, Parry GC, Guan X, Maher P, Levin EG. Inhibition of cell migration and angiogenesis by the amino-terminal fragment of 24kD basic fibroblast growth factor. J Biol Chem 2002; 277: 31056-61.
108. Neufeld G, Gospodarowicz D. Protamine sulfate inhibits mitogenic activities of the extracellular matrix and fibroblast growth factor, but potentiates that of epidermal growth factor. J Cell Physiol 1987; 132: 287-94.
109. Brown KJ, Parish CR. Histidine-rich glycoprotein and platelet factor 4 mask heparan sulfate proteoglycans recognized by acidic and basic fibroblast growth factor. Biochemistry 1994; 33: 13918-27.
110. Reis RC, Schuppan D, Barreto AC, Bauer M, Bork JP, Hassler G, et al. Endostatin competes with bFGF for binding to heparin-like glycosaminoglycans. Biochem Biophys Res Commun 2005; 333: 976-83.
111. Plum SM, Vu HA, Mercer B, Fogler WE, Fortier AH. Generation of a specific immunological response to FGF-2 does not affect wound healing or reproduction. Immunopharmacol Immunotoxicol 2004; 26: 29-41.
112. Miao RQ, Agata J, Chao L, Chao J. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 2002; 100: 3245-52.
113. Presta M, Rusnati M, Urbinati C, Sommer A, Ragnotti G. Biologically active synthetic fragments of human basic fibroblast growth factor (bFGF): identification of two Asp-Gly-Arg-containing domains involved in the mitogenic activity of bFGF in endothelial cells. J Cell Physiol 1991; 149: 512-24.
114. Kumar CC, Malkowski M, Yin Z, Tanghetti E, Yaremko B, Nechuta T, et al. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Cancer Res 2001; 61: 2232-8.
115. Belvisi L, Riccioni T, Marcellini M, Vesci L, Chiarucci I, Efrati D, et al. Biological and molecular properties of a new alpha(v)beta3/ alpha(v)beta5 integrin antagonist. Mol Cancer Ther 2005; 4: 1670-80.
116. Yeh CH, Peng HC, Yang RS, Huang TF. Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v)beta(3) blockade of endothelial cells. Mol Pharmacol 2001; 59: 1333-42.
117. Collen A, Hanemaaijer R, Lupu F, Quax PH, van Lent N, Grimbergen J, et al. Membrane-type matrix metalloproteinase-mediated angiogenesis in a fibrin-collagen matrix. Blood 2003; 101: 1810-7.
118. Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R, et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2003; 114: 171-80.
119. Bauvois B, Dumont J, Mathiot C, Kolb JP. Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons. Leukemia 2002; 16: 791-8.
120. Bastaki M, Nelli EE, Dell'Era P, Rusnati M, Molinari-Tosatti MP, Parolini S, et al. Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium. A study of aortic and microvascular endothelial cell lines. Arterioscler Thromb Vasc Biol 1997; 17: 454-64.
121. Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA, et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996; 56: 2428-33.
122. Blei F, Wilson EL, Mignatti P, Rifkin DB. Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol 1993; 155: 568-78.
123. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004; 10: 415-27.
124. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001; 61: 6413-22.
125. Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 1999; 94: 4143-55.
126. Belleri M, Ribatti D, Nicoli S, Cotelli F, Forti L, Vannini V, et al. Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4′-trimethoxystilbene. Mol Pharmacol 2005; 67: 1451-9.
127. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996; 2: 1843-9.
128. Taraboletti G, Micheletti G, Rieppi M, Poli M, Turatto M, Rossi C, et al. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clin Cancer Res 2002; 8: 1182-8.
129. Abe M, Inoue D, Matsunaga K, Ohizumi Y, Ueda H, Asano T, et al. Goniodomin A, an antifungal polyether macrolide, exhibits antiangiogenic activities via inhibition of actin reorganization in endothelial cells. J Cell Physiol 2002; 190: 109-16.
130. Wildiers H, Ahmed B, Guetens G, De Boeck G, de Bruijn EA, Landuyt W, et al. Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence. Eur J Cancer 2004; 40: 284-90.
131. Kwon HJ, Shim JS, Kim JH, Cho HY, Yum YN, Kim SH, et al. Betulinic acid inhibits growth factor-induced in vitro angiogenesis via the modulation of mitochondrial function in endothelial cells. Jpn J Cancer Res 2002; 93: 417-25.
132. Shao ZM, Shen ZZ, Liu CH, Sartippour MR, Go VL, Heber D, et al. Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int J Cancer 2002; 98: 234-40.
133. Mohan R, Sivak J, Ashton P, Russo LA, Pham BQ, Kasahara N, et al. Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. J Biol Chem 2000; 275: 10405-12.
134. Sartippour MR, Heber D, Zhang L, Beatty P, Elashoff D, Elashoff R, et al. Inhibition of fibroblast growth factors by green tea. Int J Oncol 2002; 21: 487-91.
135. Chow LM, Chui CH, Tang JC, Lau FY, Yau MY, Cheng GY, et al. Anti-angiogenic potential of Gleditsia sinensis fruit extract. Int J Mol Med 2003; 12: 269-73.
136. Liu Y, Ahmad H, Luo Y. Gardiner DT, Gunasekera RS, McKeehan WL, et al. Citrus pectin: characterization and inhibitory effect on fibroblast growth factor-receptor interaction. J Agric Food Chem 2001; 49: 3051-7.
137. Huh JE, Lee EO, Kim MS, Kang KS, Kim CH, Cha BC, et al. Penta-O-galloyl-beta-D-glucose suppresses tumor growth via inhibition of angiogenesis and stimulation of apoptosis: roles of cyclooxygenase-2 and mitogen-activated protein kinase pathways. Carcinogenesis 2005; 26: 1436-45.
138. Brakenhielm E, Cao R, Cao Y. Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J 2001; 15: 1798-800.
139. Jeon KS, Na HJ, Kim YM, Kwon HJ. Antiangiogenic activity of 4-O-methylgallic acid from Canavalia gladiata, a dietary legume. Biochem Biophys Res Commun 2005; 330: 1268-74.
140. Taraboletti G, Poli M, Dossi R, Manenti L, Borsotti P, Faircloth GT, et al. Antiangiogenic activity of aplidine, a new agent of marine origin. Br J Cancer 2004; 90: 2418-24.
141. Tong Y, Zhang X, Tian F, Yi Y, Xu Q, Li L, et al. Philinopside A, a novel marine-derived compound possessing dual anti-angiogenic and anti-tumor effects. Int J Cancer 2005; 114: 843-53.
142. Tong Y, Zhang X, Zhao W, Zhang Y, Lang J, Shi Y. et al. Anti-angiogenic effects of Shiraiachrome A, a compound isolated from a Chinese folk medicine used to treat rheumatoid arthritis. Eur J Pharmacol 2004; 494: 101-9.
143. Hoffman R, Burns WW 3rd, Paper DH. Selective inhibition of cell proliferation and DNA synthesis by the polysulphated carbohydrate 1-carrageenan. Cancer Chemother Pharmacol 1995; 36: 325-34.
144. Dupont E, Falardeau P, Mousa SA, Dimitriadou V, Pepin MC, Wang T, et al. Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin Exp Metastasis 2002; 19: 145-53.
145. Klauber N, Browne F, Anand-Apte B, D'Amato RJ. New activity of spironolactone. Inhibition of angiogenesis in vitro and in vivo. Circulation 1996; 94:2566-71.
146. Koyama S, Takagi H, Otani A, Suzuma K, Nishimura K, Honda Y. Tranilast inhibits protein kinase C-dependent signalling pathway linked to angiogenic activities and gene expression of retinal microcapillary endothelial cells. Br J Pharmacol 1999; 127: 537-45.
147. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302: 1055-61.
148. Pai R, Szabo IL, Kawanaka H, Soreghan BA, Jones MK, Tarnawski AS. Indomethacin inhibiti endothelial cell proliferation by suppressing cell cycle proteins and PRB phosphorylation: a key to its antiangiogenic action? Mol Cell Biol Res Commun 2000; 4: 111-6.
149. Vincent L, Soria C, Mirshahi F, Opolon P, Mishal Z, Vannier JP, et al. Corivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arterioscler Thromb Vasc Biol 2002; 22: 623-9.
150. Klein-Soyer C, Cazenave JP, Herbert JM, Maffrand JP. SR 25989 inhibits healing of a mechanical wound of confluent human saphenous vein endothelial cells which is modulated by standard heparin and growth factors. J Cell Physiol 1994; 160: 316-22.
151. Spandau UH, Sauder G, Schubert U, Hammes HP, Jonas JB. Effect of triamcinolone acetonide on proliferation of retinal endothelial cells in vitro and in vivo. Br J Ophthalmol 2005; 89: 745-7.
152. Chen W, Li L, Zhu J, Liu J, Soria J, Soria C, et al. Control of angiogenesis by inhibitor of phospholipase A2. Chin Med Sci J 2004; 19: 6-12.
153. Sulpice E, Bryckaert M, Lacour J, Contreres JO, Tobelem G. Platelet factor 4 inhibits FGF2-induced endothelial cell proliferation via the extracellular signal-regulated kinase pathway but not by the phosphatidylinositol 3-kinase pathway. Blood 2002; 100: 3087-94.
154. Feitsma K, Hausser H, Robenek H, Kresse H, Vischer P. Interaction of thrombospondin-1 and heparan sulfate from endothelial cells. Structural requirements of heparan sulfate. J Biol Chem 2000; 275: 9396-402.
155. Dawson DW, Volpert OV, Pearce SF, Schneider AJ, Silverstein RL, Henkin J, et al. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol 1999; 55: 332-8.
156. Aguzzi MS, Giampietri C, De Marchis F, Padula F, Gaeta R, Ragone G, et al. RGDS peptide induces caspase 8 and caspase 9 activation in human endothelial cells. Blood 2004; 103: 4180-7.
157. Ribatti D, Vacca A, Merchionne F. Presta M. Antiangiogenesis by chemotherapeutic agents. Mini Rev Med Chem 2005; 5: 313-7.
158. Keledjian K, Garrison JB, Kyprianou N. Doxazosin inhibits human vascular
159. Gelati M, Corsini E, Frigerio S, Pollo B. Broggi G, Croci D, et al. Effects of thalidomide on parameters involved in angiogenesis: an in vitro study. J Neurooncol 2003; 64: 193-201.
160. Gagliardi AR, Hennig B, Collins DC. Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors. Anticancer Res 1996; 16: 1101-6.
161. Ashino-Fuse H, Takano Y, Oikawa T, Shimamura M, Iwaguchi T. Medroxyprogesterone acetate, an anti-cancer and anti-angiogenic steroid, inhibits the plasminogen activator in bovine endothelial cells. Int J Cancer 1989; 44: 859-64.
162. Nakashio A, Fujita N, Tsuruo T. Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway. Int J Cancer 2002; 98: 36-41.
163. Presta M, Belleri M, Vacca A, Ribatti D. Anti-angiogenic activity of the purine analog 6-thioguanine. Leukemia 2002; 16: 1490-9.
164. Basaki Y, Aoyagi K, Chikahisa L, Miyadera K, Hashimoto A, Yonekura K, et al. UFT and its metabolites inhibit cancer-induced angiogenesis. Via a VEGF-related pathway. Oncology (Huntingt) 2000; 14: 68-71.
165. Shailubhai K, Dheer S, Picker D, Kaur G, Sausville EA, Jacob GS. Atiprimod is an inhibitor of cancer cell proliferation and angiogenesis. J Exp Ther Oncol 2004; 4: 267-79.
166. Yamayoshi T, Nagayasu T, Matsumoto K, Abo T, Hishikawa Y, Koji T. Expression of keratinocyte growth factor/fibroblast growth factor-7 and its receptor in human lung cancer: correlation with tumour proliferative activity and patient prognosis. J Pathol 2004; 204: 110-8.
167. Gnanapragasam VJ, Robinson MC, Marsh C, Robson CN, Hamdy FC, Leung HY. FGF8 isoform b expression in human prostate cancer. Br J Cancer 2003; 88: 1432-8.
168. Heer R, Douglas D, Mathers M, Robson C, Leung H. Fibroblast growth factor 17 is over-expressed in human prostate cancer. J Pathol 2004; 204: 578-86.
169. Auguste P, Gursel DB, Lemiere S, Reimers D, Cuevas P, Carceller F, et al. Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms. Cancer Res 2001; 61: 1717-26.
170. Polnaszek N, Kwabi-Addo B, Peterson LE, Ozen M, Greenberg NM, Ortega S, et al. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res 2003; 63: 5754-60.
171. Hagedom M, Bikfalvi A. Target molecules for anti-angiogenic therapy: from basic research to clinical trials. Crit Rev Oncol Hematol 2000; 34: 89-110.
172. Ziche M, Donnini S, Morbidelli L. Development of new drugs in angiogenesis. Curr Drug Targets 2004; 5: 485-93.
173. Patel SR, Jenkins J, Papadopolous N, Burgess MA, Plager C, Gutterman J, et al. Pilot study of vitaxin-an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer 2001; 92: 1347-8.
174. Posey JA, Khazaeli MB, DelGrosso A, Saleh MN, Lin CY, Huse W, et al. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 2001; 16: 125-32.
175. Huang S, Bucana CD, Van Arsdall M, Fidler IJ. Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene 2002; 21: 2504-12.
176. Cassinelli G, Lanzi C, Supino R, Pratesi G, Zuco V, Laccabue D, et al. Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer. Clin Cancer Res 2002; 8: 2647-54.
177. Hotchkiss KA, Ashton AW, Mahmood R, Russell RG, Sparano JA, Schwartz EL. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther 2002; 1: 1191-200.
178. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001; 7: 1459-65.
179. Ginns LC, Roberts DH, Mark EJ, Brusch JL, Marler JJ. Pulmonary capillary hemangiomatosis with atypical endotheliomatosis: successful antiangiogenic therapy with doxycycline. Chest 2003; 124: 2017-22.
180. Dmoszynska A, Bojarska-Junak A, Domanski D, Rolinski J, Hus M, Soroka-Wojtaszko M. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. Leuk Lymphoma 2002; 43: 401-6.
181. Ferretti G, Fabi A, Carlini P, Papaldo P, Cordiali Fei P, Di Cosimo S. et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 2005; 69: 35-43.
182. Bianco C, Tortora G, Baldassarre G, Caputo R, Fontanini G, Chine S, et al. 8-Chloro-cyclic AMP inhibits autocrine and angiogenic growth factor production in human colorectal and breast cancer. Clin Cancer Res 1997; 3: 439-48.
183. Sasamura H, Takahashi A, Miyao N, Yanase M, Masumori N, Kitamura H, et al. Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma. Br J Cancer 2002; 86: 768-73.
184. Fujimoto J, Hori M, Ichigo S, Hirose R, Sakaguchi H, Tamaya T. Plausible novel therapeutic strategy of uterine endometrial cancer with reduction of basic fibroblast growth factor secretion by progestin and O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470). Cancer Lett 1997; 113: 187-94.
185. Wesley UV, McGroarty M, Homoyouni A. Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway. Cancer Res 2005; 65: 1325-34.
186. Huang SF, Kim SJ, Lee AT, Karashima T, Bucana C, Kedar D, et al. Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel. Cancer Res 2002; 62: 5720-6.
187. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997; 17: 4015-23.
188. Faris M, Ensoli B, Kokot N, Nel AE. Inflammatory cytokines induce the expression of basic fibroblast growth factor (bFGF) isoforms required for the growth of Kaposi's sarcoma and endothelial cells through the activation of AP-1 response elements in the bFGF promoter. AIDS 1998; 12: 19-27.
189. Khachigian LM. Early growth response-1: blocking angiogenesis by shooting the messenger. Cell Cycle 2004; 3: 10-1.
190. Maier JA, Morelli D, Menard S, Colnaghi MI, Balsari A. Tumor-necrosis-factor-induced fibroblast growth factor-1 acts as a survival factor in a transformed endothelial cell line. Am J Pathol 1996; 149: 945-52.
191. Lee HT, Lee JG, Na M, Kay EP. FGF-2 induced by interleukin-1 beta through the action of phosphatidylinositol 3-kinase mediates endothelial mesenchymal transformation in corneal endothelial cells. J Biol Chem 2004; 279: 32325-32.
192. Albuquerque ML, Akiyama SK, Schnaper HW. Basic fibroblast growth factor release by human coronary artery endothelial cells is enhanced by matrix proteins, l7beta-estradiol, and a PKC signaling pathway. Exp Cell Res 1998; 245: 163-9.
193. Patel S, Leal AD, Gorski DH. The homeobox gene Gax inhibits angiogenesis through inhibition of nuclear factor-kappaB-dependent endothelial cell gene expression. Cancer Res 2005; 65: 1414-24.
194. Hanafusa H, Torii S, Yasunaga T, Nishida E. Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nat Cell Biol 2002; 4: 850-8.
195. Kaur G, Belotti D, Burger AM, Fisher-Nielson K, Borsotti P, Riccardi E, et al. Antiangiogenic properties of 17-(dimethylamino-ethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res 2004; 10: 4813-21.
196. Kroon ME, van Schie ML, van der Vecht B, van Hinsbergh VW, Koolwijk P. Collagen type 1 retards tube formation by human microvascular endothelial cells in a fibrin matrix. Angiogenesis 2002; 5: 257-65.
197. Staton CA, Brown NJ, Rodgers GR, Corke KP, Tazzyman S, Underwood JC, et al. Alphastatin, a 24-amino acid fragment of human fibrinogen, is a potent new inhibitor of activated endothelial cells in vitro and in vivo. Blood 2004; 103: 601-6.
198. Dixelius J, Cross M, Matsumoto T, Sasaki T, Timpl R, Claesson-Welsh L. Endostatin regulates endothelial cell adhesion and cytoskeletal organization. Cancer Res 2002; 62: 1944-7.
199. Dixelius J, Larsson H, Sasaki T, Holmqvist K, Lu L, Engstrom A, et al. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 2000; 95: 3403-11.
200. Guan X, Juarez JC, Qi X, Shipulina NV, Shaw DE, Morgan WT, et al. Histidine-proline rich glycoprotein (HPRG) binds and transduces anti-angiogenic signals through cell surface tropomyosin on endothelial cells. Thromb Haemost 2004; 92: 403-12.
201. Ashton AW, Cheng Y, Helisch A, Ware JA. Thromboxane A2 receptor agonists antagonize the proangiogenic effects of fibroblast growth factor-2: role of receptor internalization, thrombospondin-1, and alpha(v)beta3. Circ Res 2004; 94: 735-42.
202. Redlitz A, Daum G, Sage EH. Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells. J Vasc Res 1999; 36: 28-34.
203. Duenas Z, Torner L, Corbacho AM, Ochoa A, Gutierrez-Ospina G, Lopez-Barrera F, et al. Inhibition of rat corneal angiogenesis by 16-kDA prolactin and by endogenous prolactin-like molecules. Invest Ophthalmol Vis Sci 1999; 40: 2498-505.
204. Kanda S, Mochizuki Y, Miyata Y, Kanetake H, Yamamoto N. Effects of vitamin D(3)-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis. J Natl Cancer Inst 2002; 94: 1311-9.
205. Baiguera S, Conconi MT, Guidolin D, Mazzocchi G, Malendowicz LK, Parnigotto PP, et al. Ghrelin inhibits in vitro angiogenic activity of rat brain microvascular endothelial cells. Int J Mol Med 2004; 14: 849-54.
206. Rikitake Y, Kawashima S, Yamashita T, Ueyama T, Ishido S, Hotta H, et al. Lysophosphatidylcholine inhibits endothelial cell migration and proliferation via inhibition of the extracellular signal-regulated kinase pathway. Arterioscler Thromb Vasc Biol 2000; 20: 1006-12.
207. Zhang JC, Donate F, Qi X, Ziats NP, Juarez JC, Mazar AP, et al. The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. Proc Natl Acad Sci USA 2002; 99: 12224-9.
208. Kim J, Cheon IS, Won YJ, Na HJ, Kim YM, Choe J. IL-4 inhibits cell cycle progression of human umbilical vein endothelial cells by affecting p53, p21(Waf1), cyclin D1, and cyclin E expression. Mol Cells 2003; 16: 92-6.
209. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996; 87: 3877-82.
210. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995; 182: 155-62.
211. Kanda S, Mochizuki Y, Nakamura T, Miyata Y, Matsuyama T, Kanetake H. Pigment epithelium-derived factor inhibits fibroblast-growth-factor-2-induced capillary morphogenesis of endothelial cells through Fyn. J Cell Sci 2005; 118: 961-70.
212. Kaur B, Brat DJ, Devi NS, Van Meir EG. Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene 2005; 24: 3632-42.
213. Pike SE, Yao L, Jones KD, Cherney B, Appella, E, Sakaguchi K, et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 1998; 188: 2349-56.
214. Guo YL, Wang S, Colman RW. Kininostatin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells. Arterioscler Thromb Vasc Biol 2001; 21: 1427-33.
215. Lafleur MA, Handsley MM, Knauper V, Murphy G, Edwards DR. Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). J Cell Sci 2002; 115: 3427-38.
216. Norioka K, Mitaka T, Mochizuki Y, Hara M, Kawagoe M, Nakamura H. Interaction of interleukin-1 and interferon-gamma on fibroblast growth factor-induced angiogenesis. Jpn J Cancer Res 1994; 85: 522-9.
217. Sato N, Nariuchi H, Tsuruoka N, Nishihara T, Beitz JG, Calabresi P, et al. Actions of TNF and IFN-gamma on angiogenesis in vitro. J Invest Dermatol 1990; 95: 85S-89S.
218. Grant MB, Caballero S, Millard WJ. Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization. Regul Pept 1993; 48: 267-78.
219. Schulter V, Koolwijk P, Peters E, Frank S, Hrzenjak A, Graier WF, et al. Impact of apolipoprotein(a) on in vitro angiogenesis. Arterioscler Thromb Vasc Biol 2001; 21: 433-8.
220. Kessler O, Shraga-Heled N, Lange T, Gutmann-Raviv N, Sabo E, Baruch L, et al. Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res 2004; 64: 1008-15.
221. Foxall C, Wei Z, Schaefer ME, Casabonne M, Fugedi P, Peto C, et al. Sulfated malto-oligosaccharides bind to basic FGF, inhibit endothelial cell proliferation, and disrupt endothelial cell tube formation. J Cell Physiol 1996; 168: 657-67.
222. Kasbauer CW, Paper DH, Franz G. Sulfated beta-(1->4)-galacto-oligosaccharides and their effect on angiogenesis. Carbohydr Res 2001; 330: 427-30.
223. Miao HQ, Ornitz DM, Aingorn E, Ben-Sasson SA, Vlodavsky I. Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound. J Clin Invest 1997; 99: 1565-75.
224. Hasan J, Shnyder SD, Clamp AR, McGown AT, Bicknell R, Presta M, et al. Heparin octasaccharides inhibit angiogenesis in vivo. Clin Cancer Res 2005; 11: 8172-9.
225. Giraux JL, Matou S, Bros A, Tapon-Bretaudiere J, Letourneur D, Fischer AM. Modulation of human endothelial cell proliferation and migration by fucoidan and heparin. Eur J Cell Biol 1998; 77: 352-9.
226. Chabut D, Fischer AM, Colliec-Jouault S, Laurendeau I, Matou S, Le Bonniec B, et al. Low molecular weight fucoidan and heparin enhance the basic fibroblast growth factor-induced tube formation of endothelial cells through heparan sulfate-dependent alpha6 overexpression. Mol Pharmacol 2003; 64: 696-702.
227. Gagliardi AR, Taylor MF, Collins DC. Uptake of suramin by human microvascular endothelial cells. Cancer Lett 1998; 125: 97-102.
228. Takano S, Gately S, Neville ME, Herblin WF, Gross JL, Engelhard H, et al. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 1994; 54: 2654-60.
229. Sola F, Gualandris A, Belleri M, Giuliani R, Coltrini D, Bastaki M, et al. Endothelial cells overexpressing basic fibroblast growth factor (FGF-2) induce vascular tumors in immunodeficient mice. Angiogenesis 1997; 1: 102-16.
230. Aviezer D, Cotton S, David M, Segev A, Khaselev N, Galili N, et al. Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression, and metastasis. Cancer Res 2000; 60: 2973-80.
231. Benelli U, Bocci G, Danesi R, Lepri A, Bernardini N, Bianchi F, et al. The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization. Exp Eye Res 1998; 67: 133-42.
232. Casu B, Guerrini M, Guglieri S, Naggi A, Perez M, Torri G, et al. Undersulfated and glycol-split heparins endowed with antiangiogenic activity. J Med Chem 2004; 47: 838-48.
233. Liekens S, Leali D, Neyts J, Esnouf R, Rusnati M, Dell'Era P, et al. Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds. Mol Pharmacol 1999; 56: 204-13.
234. Liekens S, Neyts J, Degreve B, De Clercq E. The sulfonic acid polymers PAMPS [poly(2-acrylamido-2-methyl-1-propanesulfonic acid)] and related analogues are highly potent inhibitors of angiogenesis. Oncol Res 1997; 9: 173-81.
235. Sakairi N, Kuzuhara H, Okamoto T, Yajima M. Synthesis and biological evaluation of 2-amino-2-deoxy- and 6-amino-6-deoxy-cyclomaltoheptaose polysulfates as synergists for angiogenesis inhibition. Bioorg Med Chem 1996; 4: 2187-92.
236. Gagliardi AR, Collins DC. Inhibition of angiogenesis by aurintricarboxylic acid. Anticancer Res 1994; 14: 475-9.
237. Kitajima I, Unoki K, Maruyama I. Phosphorothioate oligodeoxynucleotides inhibit basic fibroblast growth factor-induced angiogenesis in vitro and in vivo. Antisense Nucleic Acid Drug Dev 1999; 9: 233-9.
238. Ziche M, Morbidelli L, Alessandri G, Gullino PM. Angiogenesis can be stimulated or repressed in vivo by a change in GM3:GD3 ganglioside ratio. Lab Invest 1992; 67: 711-5.
239. Vucenik I, Passaniti A, Vitolo MI, Tantivejkul K, Eggleton P, Shamsuddin AM. Anti-angiogenic activity of inositol hexaphosphate (IP6). Carcinogenesis 2004; 25: 2115-23.
240. Heryanto B, Lipson KE, Rogers PA. Effect of angiogenesis inhibitors on oestrogen-mediated endometrial endothelial cell proliferation in the ovariectomized mouse. Reproduction 2003; 125: 337-46.
241. Wang LL, Li JJ, Zheng ZB, Liu HY, Du GJ, Li S. Antitumor activities of a novel indolin-2-ketone compound, Z24: more potent inhibition on bFGF-induced angiogenesis and bcl-2 overexpressing cancer cells. Eur J Pharmacol 2004; 502: 1-10.
242. Dimitroff CJ, Klohs W, Sharma A, Pera P, Driscoll D, Veith J, et al. Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs 1999; 17: 121-35.
243. Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossi AM, et al. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res 2003; 63: 7301-9.
244. Alavi A, Hood JD, Frausto R, Stupack DG, Cheresh DA. Role of Raf in vascular protection from distinct apoptotic stimuli. Science 2003; 301: 94-6.
245. Giuliani R, Bastaki M, Coltrini D, Prests. M. Role of endothelial cell extracellular signal-regulated kinase1/2 in urokinase-type plasminogen activator upregulation and in vitro angiogenesis by fibroblast growth factor-2. J Cell Sci 1999; 112 (Pt 15): 2597-606.
246. Pintucci G, Yu PJ, Sharony R, Baumann FG, Saponara F, Frasca A, et al. Induction of stromelysin-1 (MMP-3) by fibroblast growth factor-2 (FGF-2) in FGF-2-/- microvascular endothelial cells requires prolonged activation of extracellular signal-regulated kinases-1 and -2 (ERK-1/2). J Cell Biochem 2003; 90: 1015-25.
247. Naik MU, Vuppalanchi D, Naik UP. Essential role of junctional adhesion molecule-1 in basic fibroblast growth factor-induced endothelial cell migration. Arterioscler Thromb Vasc Biol 2003; 23: 2165-71.
248. Bhagwat SV, Petrovic N, Okamoto Y, Shapiro LH. The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis. Blood 2003; 101: 1818-26.
249. Kuzuya M, Satake S, Ramos MA, Kanda S, Koike T, Yoshino K, et al. Induction of spoptotic cell death in vascular endothelial cells cultured in three-dimensional collagen lattice. Exp Cell Res 1999; 248: 498-508.
250. Santiago FS, Lowe HC, Day FL, Chesterman CN, Khachigian LM. Early growth response factor-1 induction by injury is triggered by release and paracrine activation by fibroblast growth factor-2. Am J Pathol 1999; 154: 937-44.
251. Hata Y, Rook SL, Aiello LP. Basic fibroblast growth factor induces expression of VEGF receptor KDR through a protein kinase C and p44/p42 mitogen-activated protein kinase-dependent pathway. Diabetes 1999; 48: 1145-55.
252. Langford D, Hurford R, Hashimoto M, Digicaylioglu M, Masliah E. Signalling crosstalk in FGF2-mediated protection of endothelial cells from HIV-gp 120. BMC Neurosci 2005; 6: 8.
253. Zubilewicz A, Hecquet C, Jeanny JC, Soubrane G, Courtois Y, Mascarelli F. Two distinct signalling pathways are involved in FGF2-stimulated proliferation of choriocapillary endothelial cells: a comparative study with VEGF. Oncogene 2001; 20: 1403-13.
254. Tanaka K, Abe M, Sato Y. Roles of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in the signal transduction of basic fibroblast growth factor in endothelial cells during angiogenesis. Jpn J Cancer Res 1999; 90: 647-54.
255. Lu L, Holmqvist K, Cross M, Welsh M. Role of the Src homology 2 domain-containing protein Shb in murine brain endothelial cell proliferation and differentiation. Cell Growth Differ 2002; 13: 141-8.
256. Kay EP, Park SY, Ko MK, Lee SC. Fibroblast growth factor 2 uses PLC-gammal for cell proliferation and PI3-kinase for alteration of cell shape and cell proliferation in corneal endothelial cells. Mol Vis 1998; 4: 22.
257. Kent KC, Mii S, Harrington EO, Chang JD, Mallette S, Ware JA. Requirement for protein kinase C activation in basic fibroblast growth factor-induced human endothelial cell proliferation. Circ Res 1995; 77: 231-8.
258. Presta, M, Tiberio L, Rusnati M, Dell'Era P, Ragnotti G. Basic fibroblast growth factor requires a long-lasting activation of protein kinase C to induce cell proliferation in transformed fetal bovine aortic endothelial cells. Cell Regul 1991; 2: 719-26.
259. Haimovitz-Friedman A, Balaban N, McLoughlin M, Ehleiter D, Michaeli J, Vlodavsky I, et al. Protein kinase C mediates basic fibroblast growth factor protection of endothelial. cells against radiation-induced apoptosis. Cancer Res 1994; 54: 2591-7.
260. Takano S, Gately S, Jiang JB, Brem S. A diaminoantraquinone inhibitor of angiogenesis. J Pharmacol Exp Ther 1994; 271: 1027-33.
261. Hu DE, Fan TP. Protein kinase C inhibitor calphostin C prevents cytokine-induced angiogenesis in the rat. Inflammation 1995; 19: 39-54.
262. Klint P, Kanda S, Kloog Y, Claesson-Welsh L. Contribution of Src and Ras pathways in FGF-2 induced endothelial cell differentiation. Oncogene 1999; 18: 3354-64.
263. van Hinsbergh VW, Vermeer M, Koolwijk P, Grimbergen J, Kooistra T. Genistein reduces tumor necrosis factor alpha-induced plasminogen activator inhibitor-1 transcription but not urokinase expression in human endothelial cells. Blood 1994; 84: 2984-91.
264. Shono T, Kanetake H, Kanda S. The role of mitogen-activated protein kinase activation within focal adhesions in chemotaxis toward FGF-2 by murine brain capillary endothelial cells. Exp Cell Res 2001; 264: 275-83.
265. Kilarski WW, Jura N, Gerwins P. Inactivation of Src family kinases inhibits angiogenesis in vivo: implications for a mechanism involving organization of the actin cytoskeleton. Exp Cell Res 2003; 291: 70-82.
266. Lee HT, Kim TY, Kay EP. Cdk4 and p27Kip1 play a role in PLC-gamma1-mediated mitogenic: signaling pathway of 18 kDa FGF-2 in corneal endothelial cells. Mol Vis 2002; 8: 17-25.
267. Sa G, Fox PL. Basic fibroblast growth factor-stimulated endothelial cell movement is mediated by a pertussis toxin-sensitive pathway regulating phospholipase A2 activity. J Biol Chem 1994; 269: 3219-25.
268. Anwar KN, Fazal F, Malik AB, Rahman A. RhoA/Rho-associated kinase pathway selectively regulates thrombin-induced intercellular adhesion molecule-1 expression in endothelial cells via activation of I kappa B kinase beta and phosphorylation of RelA/p65. J Immunol 2004; 173: 6965-72.
269. Soriano JV, Liu N, Gan Y, Yao ZJ, Ishibashi T, Underhill C, et al. Inhibition of angiogenesis by growth factor receptor bound protein 2-Src homology 2 domain bound antagonists. Mol Cancer Ther 2004; 3: 1289-99.
270. D'Angelo G, Lee H, Weiner RI. cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. J Cell Biochem 1997; 67: 353-66.
271. Forough R, Weylie B, Patel C, Ambrus S, Singh US, Zhu J. Role of AKT/PKB signaling in fibroblast growth factor-1 (FGF-1)-induced angiogenesis in the chicken chorioallantoic membrane (CAM). J Cell Biochem 2005; 94: 109-16.
272. Hoffmann S, He S, Jin ML, Masiero L, Wiedemann P, Ryan SJ, et al. Carboxyamido-triazole modulates retinal pigment epithelial and choroidal endothelial cell attachment, migration, proliferation, and MMP-2 secretion of choroidal endothelial cells. Curr Eye Res 2005; 30: 103-13.
273. Wijelath ES, Carlsen B, Cole T, Chen J, Kothari S, Hammond WP. Oncostatin M induces basic fibroblast growth factor expression in endothelial cells and promotes endothelial cell proliferation, migration and spindle morphology. J Cell Sci 1997; 110 (Pt 7): 871-9.
274. Danesi R, Del Bianchi S, Soldani P, Campagni A, La Rocca RV, Myers CE, et al. Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. Br J Cancer 1993; 68: 932-8.
275. Cross MJ, Hodgkin MN, Roberts S, Landgren E, Wakelam. MJ, Claesson-Welsh L. Tyrosine 766 in the fibroblast growth factor receptor- 1 is required for FGF-stimulation of phospholipase C, phospholipase D, phospholipase A(2), phosphoinositide 3-kinase and cytoskeletal reorganisation in porcine aortic endothelial cells. J Cell Sci 2000; 113 (Pt 4): 643-51.
276. Lee SH, Schloss DJ, Swain JL. Maintenance of vascular integrity in the embryo requires signaling through the fibroblast growth factor receptor. J Biol Chem 2000; 275: 33679-87.
277. Hood JD, Frausto R, Kiosses WB, Schwartz MA, Cheresh DA. Differential alphav, integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J Cell Biol 2003; 162: 933-43.
278. Mettouchi A, Klein S, Guo W, Lopez-Lago M, Lemichez E, Westwick JK, et al. Integrin-specific activation of Rac controls progression through the G(1) phase of the cell cycle. Mol Cell 2001; 8: 115-27.
279. Cross MJ, Lu L, Magnusson P, Nyqvist D, Holmqvist K, Welsh M, et al. The Shb adaptor protein binds to tyrosine 766 in the FGFR- 1 and regulates the Ras/MEK/MAPK pathway via FRS2 phosphorylation in endothelial cells. Mol Biol Cell 2002; 13: 2881-93.
280. Murakami M, Horowitz A, Tang S, Ware JA, Simons M. Protein kinase C (PKC) delta regulates PKCalpha activity in a Syndecan-4-dependent manner. J Biol Chem 2002; 277: 20367-71.
281. Kanda S, Lerner EC, Tsuda S, Shono T, Kanetake H, Smithgall TE. The nonreceptor protein-tyrosine kinase c-Fes is involved in fibroblast growth factor-2-induced chemotaxis of murine brain capillary endothelial cells. J Biol Chem 2000; 275: 10105-11.
282. Tan J, Hallahan DE. Growth factor-independent activation of protein kinase B contributes to the inherent resistance of vascular endothelium to radiation-induced apoptotic response. Cancer Res 2003; 63: 7663-7.
283. Gu Q, Wang D, Wang X, Peng R, Liu J, Jiang T, et al. Basic fibroblast growth factor inhibits radiation-induced apoptosis of HUVECs. I. The PI3K/AKT pathway and induction of phosphorylation of BAD. Radiat Res 2004; 161: 692-702.
284. Kanda S, Miyata Y, Kanetake H. Fibroblast growth factor-2-mediated capillary morphogenesis of endothelial cells requires signals via Flt-1/vascular endothelial growth factor receptor-1: possible involvement of c-Akt. J Biol Chem 2004; 279: 4007-16.
285. Tsuda S, Ohtsuru A, Yamashita S, Kanetake H, Kanda S. Role of c-Fyn in FGF-2-mediated tube-like structure formation by murine brain capillary endothelial cells. Biochem Biophys Res Commun 2002; 290: 1354-60.
286. Pourtier-Manzanedo A, Vercamer C, Van Belle E, Mattot V, Mouquet F, Vandenbunder B. Expression of an Ets-1 dominant-negative mutant perturbs normal and minor angiogenesis in a mouse ear model. Oncogene 2003; 22: 1795-806.
287. Klein S, de Fougerolles AR, Blaikie P, Khan L, Pepe A, Green CD, et al. Alpha 5 beta 1 integrin activates an NF-kappa B-dependent program of gene expression important for angiogenesis and inflammation. Mol Cell Biol 2002; 22: 5912-22.
288. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004; 5: 816-26.
289. Simons M, Horowitz A. Syndecan-4-mediated signalling. Cell Signal 2001; 13: 855-62.
290. Benelli R, Lorusso G, Albini A, Noonan DM. Cytokines and chemokines as regulators of angiogenesis in health and disease. Curr Pharm. Des 2006; 12(24): 3101-15.
291. Furness MS, Robinson TP, Ehlers T, Hubbard RB 4th, Arbiser JL, Goldsmith DJ, et al. Antiangiogenic agents: studies on fumagillin and curcumin analogs. Curr Pharm Des 2005; 11(3): 357-73.
292. Verhoef C, de Wilt JH, Verheul HM. Angiogenesis inhibitors: perspectives for medical, surgical and radiation oncology. Curr Pharm Des 2006; 12(21): 2623-30.